{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:40:34Z","timestamp":1790138434328,"version":"4.0.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"DOI":"10.1097\/qai.0b013e318050d66c","type":"journal-article","created":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T09:03:34Z","timestamp":1175245414000},"page":"304-310","source":"Crossref","is-referenced-by-count":43,"title":["Antiretroviral Durability and Tolerability in HIV-Infected Adults Living in Urban Kenya"],"prefix":"10.1097","volume":"45","author":[{"given":"Claudia","family":"Hawkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Achenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Fryda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Ngare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210131","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00126334-200501010-00003","article-title":"Ndour CT, et al, for the ANRS 1215\/1290 Study Group. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults.","volume":"38","author":"Laurent","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl","key":"R2-8-20210131","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1097\/00002030-200317003-00013","article-title":"Access to antiretroviral drugs and AIDS management in Senegal.","volume":"17","author":"Desclaux","year":"2003","journal-title":"AIDS"},{"key":"R3-8-20210131","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1086\/431482","article-title":"Lessons learned from use of highly active antiretroviral therapy in Africa.","volume":"4","author":"Akileswaran","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R4-8-20210131","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","article-title":"Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; Antiretroviral Therapy Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.","volume":"367","author":"Braitstein","year":"2006","journal-title":"Lancet"},{"key":"R5-8-20210131","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00002030-200404090-00006","article-title":"Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.","volume":"18","author":"Coetzee","year":"2004","journal-title":"AIDS"},{"key":"R6-8-20210131","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa051908","article-title":"Antiretroviral therapy in a thousand patients with AIDS in Haiti.","volume":"353","author":"Severe","year":"2005","journal-title":"N Engl J Med"},{"key":"R7-8-20210131","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.qai.0000159668.80207.5b","article-title":"Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana.","volume":"40","author":"Wester","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-8-20210131","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00002030-200203290-00009","article-title":"Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.","volume":"16","author":"Dieleman","year":"2002","journal-title":"AIDS"},{"key":"R12-8-20210131","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.qai.0000188123.15493.43","article-title":"Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.","volume":"41","author":"Kumarasamy","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R13-8-20210131","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archinte.162.9.985","article-title":"Rifampin and rifabutin drug interactions: an update.","volume":"162","author":"Finch","year":"2002","journal-title":"Arch Intern Med"},{"key":"R14-8-20210131","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/01.aids.0000233572.59522.45","article-title":"Virological response to a triple nucleoside\/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.","volume":"20","year":"2006","journal-title":"AIDS"},{"key":"R15-8-20210131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(04)16586-0","article-title":"Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.","volume":"364","author":"Laurent","year":"2004","journal-title":"Lancet"},{"key":"R16-8-20210131","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/00002030-200310170-00019","article-title":"The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India.","volume":"17","author":"Kumarasamy","year":"2003","journal-title":"AIDS"},{"key":"R17-8-20210131","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1097\/00126334-200412150-00005","article-title":"Effectiveness of generic fixed-dose combination of highly active antiretroviral therapy for treatment of HIV infection in India.","volume":"37","author":"Pujari","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R19-8-20210131","first-page":"199","article-title":"Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in western India.","volume":"39","author":"Pujari","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-8-20210131","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00002030-200304110-00021","article-title":"Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy.","volume":"17","author":"Garcia-Benayas","year":"2003","journal-title":"AIDS"},{"key":"R22-8-20210131","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/00126334-200408010-00006","article-title":"A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.","volume":"36","author":"Jack","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R24-8-20210131","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Ruxrungtham K, et al, for the 2NN Study Team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"R25-8-20210131","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV infected subjects.","volume":"191","author":"Sanne","year":"2005","journal-title":"J Infect Dis"},{"key":"R26-8-20210131","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.aids.0000196177.65551.ea","article-title":"Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya.","volume":"20","author":"Wools-Kaloustian","year":"2006","journal-title":"AIDS"},{"key":"R27-8-20210131","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/01.qai.0000134742.26338.2f","article-title":"Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses.","volume":"38","author":"Kabugo","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl","key":"R28-8-20210131","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200317003-00002","article-title":"Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote dIvoire.","volume":"17","author":"Djomand","year":"2003","journal-title":"AIDS"},{"key":"R29-8-20210131","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-3156.2005.01409.x","article-title":"Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.","volume":"10","author":"van Oosterhout","year":"2005","journal-title":"Trop Med Int Health"},{"key":"R30-8-20210131","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0140-6736(02)09330-3","article-title":"Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients response, survival, and drug resistance.","volume":"360","author":"Weidle","year":"2002","journal-title":"Lancet"},{"key":"R31-8-20210131","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/431199","article-title":"Efficacy of antiretroviral therapy programs in resource poor settings: a meta-analysis of the published literature.","volume":"41","author":"Ivers","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"R33-8-20210131","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/00002030-200317003-00014","article-title":"Adherence to HAART and its principal determinants in a cohort of Senegalese adults.","volume":"17","author":"Laniece","year":"2003","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200707010-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:19:10Z","timestamp":1618039150000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200707010-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318050d66c","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}